Royal Bank of Canada’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $69K | Sell |
3,295
-159,932
| -98% | -$3.6M | ﹤0.01% | 5330 |
|
|
2025
Q4 | $3.75M | Sell |
163,227
-73,062
| -31% | -$2.4M | ﹤0.01% | 2656 |
|
|
2025
Q3 | $7.11M | Buy |
236,289
+226,246
| +2,253% | +$6.78M | ﹤0.01% | 2400 |
|
|
2025
Q2 | $365K | Buy |
10,043
+4,253
| +73% | +$153K | ﹤0.01% | 4707 |
|
|
2025
Q1 | $209K | Sell |
5,790
-63,952
| -92% | -$2.66M | ﹤0.01% | 4670 |
|
|
2024
Q4 | $2.93M | Buy |
69,742
+3,612
| +5% | +$179K | ﹤0.01% | 2738 |
|
|
2024
Q3 | $3.67M | Buy |
66,130
+61,452
| +1,314% | +$3.13M | ﹤0.01% | 2528 |
|
|
2024
Q2 | $191K | Sell |
4,678
-2,120
| -31% | -$90.5K | ﹤0.01% | 4806 |
|
|
2024
Q1 | $317K | Sell |
6,798
-26,449
| -80% | -$1.25M | ﹤0.01% | 4303 |
|
|
2023
Q4 | $1.59M | Sell |
33,247
-2,502
| -7% | -$97K | ﹤0.01% | 3258 |
|
|
2023
Q3 | $1.27M | Sell |
35,749
-20,986
| -37% | -$831K | ﹤0.01% | 3239 |
|
|
2023
Q2 | $2.62M | Sell |
56,735
-43
| -0.1% | -$2K | ﹤0.01% | 2625 |
|
|
2023
Q1 | $2.28M | Buy |
56,778
+52,528
| +1,236% | +$2.25M | ﹤0.01% | 2702 |
|
|
2022
Q4 | $197K | Buy |
4,250
+490
| +13% | +$19.3K | ﹤0.01% | 4900 |
|
|
2022
Q3 | $155K | Sell |
3,760
-3,092
| -45% | -$159K | ﹤0.01% | 4973 |
|
|
2022
Q2 | $410K | Sell |
6,852
-399
| -6% | -$24.6K | ﹤0.01% | 4252 |
|
|
2022
Q1 | $526K | Sell |
7,251
-1,476
| -17% | -$103K | ﹤0.01% | 4229 |
|
|
2021
Q4 | $734K | Buy |
8,727
+739
| +9% | +$60.1K | ﹤0.01% | 4129 |
|
|
2021
Q3 | $719K | Sell |
7,988
-24,018
| -75% | -$2.17M | ﹤0.01% | 4007 |
|
|
2021
Q2 | $3.05M | Buy |
32,006
+25,627
| +402% | +$2.67M | ﹤0.01% | 2695 |
|
|
2021
Q1 | $727K | Buy |
6,379
+1,418
| +29% | +$193K | ﹤0.01% | 3869 |
|
|
2020
Q4 | $686K | Buy |
4,961
+2,596
| +110% | +$308K | ﹤0.01% | 3857 |
|
|
2020
Q3 | $194K | Buy |
2,365
+1,156
| +96% | +$95.8K | ﹤0.01% | 4575 |
|
|
2020
Q2 | $95K | Buy |
1,209
+1,036
| +599% | +$68.6K | ﹤0.01% | 4880 |
|
|
2020
Q1 | $8K | Sell |
173
-2,358
| -93% | -$122K | ﹤0.01% | 5905 |
|
|
2019
Q4 | $107K | Buy |
2,531
+992
| +64% | +$40.9K | ﹤0.01% | 5051 |
|
|
2019
Q3 | $65K | Buy |
1,539
+1,334
| +651% | +$72.5K | ﹤0.01% | 5013 |
|
|
2019
Q2 | $12K | Sell |
205
-1,018
| -83% | -$64.8K | ﹤0.01% | 5968 |
|
|
2019
Q1 | $85K | Buy |
1,223
+268
| +28% | +$15.3K | ﹤0.01% | 4875 |
|
|
2018
Q4 | $42K | Sell |
955
-1,300
| -58% | -$71.1K | ﹤0.01% | 5193 |
|
|
2018
Q3 | $172K | Buy |
2,255
+230
| +11% | +$18.7K | ﹤0.01% | 4557 |
|
|
2018
Q2 | $155K | Buy |
2,025
+1,702
| +527% | +$110K | ﹤0.01% | 4559 |
|
|
2018
Q1 | $16K | Sell |
323
-271,522
| -100% | -$13.7M | ﹤0.01% | 5538 |
|
|
2017
Q4 | $12.6M | Buy |
271,845
+41,758
| +18% | +$2.05M | 0.01% | 1447 |
|
|
2017
Q3 | $12.3M | Buy |
230,087
+5,826
| +3% | +$345K | 0.01% | 1390 |
|
|
2017
Q2 | $13.9M | Buy |
224,261
+202,556
| +933% | +$12.2M | 0.01% | 1293 |
|
|
2017
Q1 | $1.47M | Sell |
21,705
-133,099
| -86% | -$10.1M | ﹤0.01% | 2778 |
|
|
2016
Q4 | $10.9M | Sell |
154,804
-6,934
| -4% | -$492K | 0.01% | 1451 |
|
|
2016
Q3 | $11.5M | Buy |
161,738
+28,314
| +21% | +$1.81M | 0.01% | 1392 |
|
|
2016
Q2 | $6.53M | Buy |
133,424
+17,941
| +16% | +$1.16M | ﹤0.01% | 1734 |
|
|
2016
Q1 | $7.31M | Buy |
115,483
+115,451
| +360,784% | +$7.55M | ﹤0.01% | 1571 |
|
|
2015
Q4 | $4K | Sell |
32
-1,766
| -98% | -$177K | ﹤0.01% | 6228 |
|
|
2015
Q3 | $173K | Sell |
1,798
-2,402
| -57% | -$275K | ﹤0.01% | 4439 |
|
|
2015
Q2 | $430K | Sell |
4,200
-7,100
| -63% | -$551K | ﹤0.01% | 3747 |
|
|
2015
Q1 | $702K | Buy |
+11,300
| New | +$628K | ﹤0.01% | 3186 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Royal Bank of Canada's RARE Position: Q1 2026 in Review
Royal Bank of Canada reduced its Ultragenyx Pharmaceutical (RARE) stake by 98% in Q1 2026, selling an estimated $3.6M and leaving 3,295 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #5330.
Royal Bank of Canada first reported a position in RARE in Q1 2015 and has held it in 45 quarters since. The position peaked at $13.9M in Q2 2017. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Royal Bank of Canada held 3,295 shares of Ultragenyx Pharmaceutical worth $69K as of Q1 2026.
- Royal Bank of Canada sold 159,932 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.6M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5330 holding.
- Royal Bank of Canada first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 45 quarters since.
- Royal Bank of Canada's Ultragenyx Pharmaceutical position peaked at $13.9M in Q2 2017.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.